Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jul;43(7):1754-5.
doi: 10.1128/AAC.43.7.1754.

Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin

R L Patron  1 , M W Climo, B P Goldstein, G L Archer
Affiliations

Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin

R L Patron et al. Antimicrob Agents Chemother. 1999 Jul.

Abstract

The rabbit model of endocarditis was used to test the effectiveness of vancomycin and two different lysostaphin dosing regimens for the treatment of infections caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin (glycopeptide-intermediate susceptible S. aureus [GISA]). Vancomycin was ineffective, with no evidence of sterilization of aortic valve vegetations. However, rates of sterilization of aortic valve vegetations were significantly better for animals treated with either a single dose of lysostaphin (43%) or lysostaphin given twice daily for 3 days (83%) than for animals treated with vancomycin. Rabbits given a single dose of lysostaphin followed by a 3-day drug-free period had mean reductions in aortic valve vegetation bacterial counts of 7.27 and 6.63 log10 CFU/g compared with those for untreated control rabbits and the vancomycin-treated group, respectively. We conclude that lysostaphin is an effective alternative for the treatment of experimental aortic valve endocarditis caused by a clinical VISA strain.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Climo M W, Markowitz S M, Williams D S, Hale-Cooper C G, Archer G L. Comparison of in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species. J Antimicrob Chemother. 1997;40:59–66. - PubMed
    1. Climo M W, Patron R L, Goldstein B P, Archer G L. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother. 1998;42:1355–1360. - PMC - PubMed
    1. Dixon R E, Goodman J S, Koenig M G. Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J Biol Med. 1968;41:62–68. - PMC - PubMed
    1. Goldberg L M, DeFranco J M, Watanakunakorn C, Hamburger M. Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin. 1967. pp. 45–53. . Antimicrob. Agents Chemother. 1966. - PubMed
    1. Harrison E F, Cropp C B. Therapeutic activity of lysostaphin in experimental staphylococcal infections. Can J Microbiol. 1967;13:93–97.

Publication types

MeSH terms